SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction

By sjmartinez • October 29, 2023

Avula V, Sharma G, Kosiborod MN, Vaduganathan M, Neilan TG, Lopez T, Dent S, Baldassarre L, Scherrer-Crosbie M, Barac A, Liu J, Deswal A, Khadke S, Yang EH, Ky B, Lenihan D, Nohria A, Dani SS, Ganatra S. SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac Dysfunction. JACC Heart Fail. 2023 Oct 12:S2213-1779(23)00596-6. doi: 10.1016/j.jchf.2023.08.026. Epub ahead of print. PMID: 37897456.

Tags: antineoplastic therapy, cardiomyopathy, Digestive Diseases, Outcomes, Publications, SGLT2 inhibitors

Rates and Factors Associated With Hepatocellular Carcinoma Diagnosis, Stage, Treatment, and Survival

Ioannou GN, Yakovchenko V, Taddei T, Monto A, Patton H, Merante M, Spoutz P, Chia L, Yudkevich J, Aytaman A, Rabiee A, John B, Blechacz[...]

The Current Landscape of Microbial Biomarkers in Gastrointestinal Disease

Kim SG, Zhao MY, Lam C, Jacobs JP. The Current Landscape of Microbial Biomarkers in Gastrointestinal Disease. Gastroenterol Clin North Am. 2026 Mar;55(1):165-184. doi: 10.1016/j.gtc.2025.10.003.[...]

Biomarkers in Irritable Bowel Syndrome: Rationale and Practical Use

Guan M, Chang L. Biomarkers in Irritable Bowel Syndrome: Rationale and Practical Use. Gastroenterol Clin North Am. 2026 Mar;55(1):91-105. doi: 10.1016/j.gtc.2025.08.002. Epub 2025 Oct 21.[...]